(Q42554235)

English

Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice

scientific article published on May 1996

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

F G Araujo

1

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

Y Suzuki

2

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

J S Remington

3

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

publication date

1 May 1996

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

European Journal of Clinical Microbiology & Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

394-397

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

Toxoplasmic encephalitis in AIDS.

1 reference

https://api.crossref.org/works/10.1007%2FBF01690096

21 January 2018

Rifabutin is active in murine models of toxoplasmosis

1 reference

https://api.crossref.org/works/10.1007%2FBF01690096

21 January 2018

In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii

1 reference

https://api.crossref.org/works/10.1007%2FBF01690096

21 January 2018

Biology of Toxoplasma gondii

1 reference

https://pubmed.ncbi.nlm.nih.gov/8793398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recent advances in the search for new drugs for treatment of toxoplasmosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8793398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with anti-L3T4 (CD4) monoclonal antibody reduces the inflammatory response in toxoplasmic encephalitis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8793398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxoplasmic encephalitis in patients with AIDS.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8793398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/8793398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New anti-protozoal agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/8793398

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01690096

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42554235&oldid=2205494515"